XXII - 22nd Century Group, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
0.7906
-0.0096 (-1.20%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.8002
Open0.8200
Bid0.8000 x 800
Ask0.7995 x 1200
Day's Range0.7850 - 0.8295
52 Week Range0.6000 - 2.4600
Volume1,490,564
Avg. Volume1,088,153
Market Cap109.778M
Beta (5Y Monthly)1.27
PE Ratio (TTM)N/A
EPS (TTM)-0.2200
Earnings DateMay 07, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    22nd Century Group Appoints James A. Mish as Chief Executive Officer and John Franzino as Chief Financial Officer

    Mish brings extensive global executive leadership experience in the development, manufacturing and commercialization of active pharmaceutical ingredients, including.

  • Thomson Reuters StreetEvents

    Edited Transcript of XXII earnings conference call or presentation 7-May-20 12:00pm GMT

    Q1 2020 22nd Century Group Inc Earnings Call

  • Read This Before Selling 22nd Century Group, Inc. (NYSEMKT:XXII) Shares
    Simply Wall St.

    Read This Before Selling 22nd Century Group, Inc. (NYSEMKT:XXII) Shares

    We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...

  • Business Wire

    22nd Century Group Reports First Quarter 2020 Financial Results

    22nd Century Group, Inc. (NYSE American: XXII) ("22nd Century" or "the Company"), a leading plant biotechnology company focused on reduced nicotine tobacco and hemp/cannabis plant genetics research and development, today reported results for the first quarter ended March 31, 2020.

  • Business Wire

    22nd Century Group Completes Successful Non-GMO Very Low Nicotine Content Tobacco Research Field Trials

    22nd Century Group, Inc. (NYSE American: XXII) ("22nd Century" or "the Company"), a leading plant biotechnology company focused on reduced nicotine tobacco and hemp/cannabis plant genetics research and development, announced today that the Company and North Carolina State University ("NCSU"), have completed successful research field trials that have validated new non-GMO (genetically modified organism) methodologies for reducing nicotine in tobacco plants. The research was partially funded by 22nd Century and was conducted by NCSU’s Department of Crop and Soil Science with project oversight provided by 22nd Century’s R&D team. The research findings and paper can be viewed at the following link: https://doi.org/10.3389/fpls.2020.00368

  • GlobeNewswire

    22nd Century Group to Announce First Quarter 2020 Financial Results on May 7, 2020

    Williamsville, NY, April 28, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII) (“22nd Century” or “the Company”), a leading plant biotechnology company focused on reduced nicotine tobacco and hemp/cannabis plant genetics research and development, will release first quarter 2020 financial results on Thursday, May 7, 2020, before the market opens. The press release will be available on 22nd Century Group’s website at www.xxiicentury.com. In conjunction with the earnings release, the Company will host a conference call on Thursday, May 7, 2020, at 8:00 a.m. ET.

  • GlobeNewswire

    FDA Announces Deadline to Submit Comments on 22nd Century Group’s MRTP Application

    WILLIAMSVILLE, NY, April 17, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII) (“22nd Century” or “the Company”), a leading plant biotechnology company focused on reduced nicotine content tobacco and hemp/cannabis plant genetics research and development, announced today that the U.S. Food and Drug Administration (FDA) has set May 18, 2020 as the deadline for the submission of public comments on the Company’s Modified Risk Tobacco Product (MRTP) Application. 22nd Century’s MRTP application seeks authorization from the FDA to allow the Company to market its reduced nicotine content cigarettes under the brand name VLN®, with pack and advertising claims stating that the product contains 95% less nicotine than conventional tobacco cigarettes, as well as related claims regarding reduced nicotine exposure.

  • GlobeNewswire

    22nd Century Group to Hold Virtual Annual Meeting of Stockholders

    Williamsville, NY, April 08, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII) (“22nd Century” or “the Company”), a leading plant biotechnology company focused on reduced nicotine tobacco and hemp/cannabis plant genetics research and development, announced today that the Company will hold its 2020 Annual Meeting of Stockholders using a virtual meeting format. The decision to move to a virtual meeting was done in order to protect the health and safety of meeting participants during the coronavirus (COVID-19) pandemic. The live webcast will be available under the Events tab on the Investor Relations section of the Company’s website at www.xxiicentury.com and will be archived for at least 90 days.

  • Does The 22nd Century Group, Inc. (NYSEMKT:XXII) Share Price Fall With The Market?
    Simply Wall St.

    Does The 22nd Century Group, Inc. (NYSEMKT:XXII) Share Price Fall With The Market?

    Anyone researching 22nd Century Group, Inc. (NYSEMKT:XXII) might want to consider the historical volatility of the...

  • Business Wire

    22nd Century Group, Inc. Files 2019 Annual Report

    22nd Century Group, Inc. (NYSE American: XXII), a leading plant biotechnology company in reduced nicotine tobacco and hemp/cannabis plant genetics research and development, yesterday filed its Annual Report on Form 10-K for the year ended December 31, 2019. A supplemental letter from Michael Zercher, President and Chief Operating Officer to shareholders is available in the Investor section of the Company’s website.

  • GlobeNewswire

    22nd Century Announces Important New Achievements with KeyGene

    WILLIAMSVILLE, N.Y. , March 11, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a leading plant biotechnology company in reduced nicotine tobacco and hemp/cannabis plant genetics research, announced today that lead scientists from 22nd Century Group and KeyGene have assembled a high quality genome sequence of two hemp/cannabis lines and established a new, proprietary hemp/cannabis bioinformatics platform. Both are believed to be among the highest quality, hemp/cannabis reference genomes in the world. “These exciting, new developments are already enabling the rapid breeding of new and proprietary hemp/cannabis plant lines with truly remarkable and potentially novel medicinal cannabinoid profiles,” said Michael Zercher, President & Chief Operating Officer of 22nd Century Group.

  • GlobeNewswire

    22nd Century Group Adds to Leadership Team

    WILLIAMSVILLE, N.Y., March 10, 2020 -- 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in reduced nicotine tobacco and.

  • GlobeNewswire

    CORRECTION: Further Support for Reducing Nicotine in Cigarettes to Non-Addictive Levels: New Studies Confirm Use of Very Low Nicotine Content Cigarettes Does Not Lead to Compensatory Smoking

    Williamsville, NY, March 04, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE AMERICAN: XXII), a plant biotechnology company that is a leader in reduced nicotine tobacco and hemp/cannabis plant research, announced that two studies published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research (AACR), report the use of cigarettes containing very low levels of nicotine did not lead to compensatory smoking, further refuting common misperceptions about these products. The two studies were led by Tracy T. Smith, PhD, Assistant Professor in the Department of Psychiatry and Behavioral Sciences at the Medical University of South Carolina and Hollings Cancer Center and were co-authored by other leading researchers of very low nicotine content cigarettes, including Professor Dorothy Hatsukami, PhD and Professor Eric Donny, PhD.

  • GlobeNewswire

    Further Support for Reducing Nicotine in Cigarettes to Non-Addictive Levels: New Studies Confirm Use

    Williamsville, NY, March 04, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE AMERICAN: XXII), a plant biotechnology company that is a leader in reduced nicotine tobacco and hemp/cannabis plant research, announced that two studies published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research (AACR), report the use of cigarettes containing very low levels of nicotine did not lead to compensatory smoking, further refuting common misperceptions about these products. The two studies were led by Tracy T. Smith, PhD, Assistant Professor in the Department of Psychiatry and Behavioral Sciences at the Medical University of South Carolina and Hollings Cancer Center and were co-authored by other leading researchers of very low nicotine content cigarettes, including Professor Dorothy Hatsukami, PhD and Professor Eric Donny, PhD.

  • If You Had Bought 22nd Century Group (NYSEMKT:XXII) Stock A Year Ago, You'd Be Sitting On A 50% Loss, Today
    Simply Wall St.

    If You Had Bought 22nd Century Group (NYSEMKT:XXII) Stock A Year Ago, You'd Be Sitting On A 50% Loss, Today

    It's easy to match the overall market return by buying an index fund. When you buy individual stocks, you can make...

  • GlobeNewswire

    22nd Century Group Appoints New Director and New Chairman

    Williamsville, NY, Jan. 13, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco and hemp/cannabis research, announced the appointment of Roger O’Brien as a new member of 22nd Century Group’s Board of Directors (the “Board”) and the appointment of Nora Sullivan, an existing director of the Board, as the new Chairman of the Board.

  • GlobeNewswire

    22nd Century Group to Present its Modified Risk Tobacco Product Application to FDA’s Tobacco Products Scientific Advisory Committee

    Williamsville, NY, Dec. 23, 2019 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco and hemp/cannabis research, announced today that the U.S. Food and Drug Administration's (FDA) Tobacco Products Scientific Advisory Committee (TPSAC) will conduct a public hearing on Friday, February 14, 2020, regarding 22nd Century Group’s Modified Risk Tobacco Product (MRTP) application for its VLNC cigarettes under the proposed brand name of VLN® cigarettes. “We welcome the opportunity to publicly present our MRTP application and detail the science and evidence supporting the reduced exposure claims for VLN® cigarettes,” said Michael Zercher, President and Chief Operating Officer of 22nd Century Group.

  • GlobeNewswire

    FDA Authorizes Marketing of 22nd Century Group’s Proprietary Moonlight® and Moonlight® Menthol Cigarettes

    Williamsville, NY, Dec. 17, 2019 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco, and hemp/cannabis plant research, announced today that the U.S. Food and Drug Administration (FDA) has found that the marketing of 22nd Century Group’s proprietary Moonlight® and Moonlight® Menthol brand cigarettes are “appropriate for the protection of the public health,” and the FDA has issued marketing orders to permit the sale of these products in the U.S. This FDA authorization follows the FDA’s review of the Premarket Tobacco Product Applications (PMTA) previously submitted by 22nd Century Group. “FDA authorization of 22nd Century’s proprietary Moonlight® and Moonlight® Menthol brand cigarettes is a major milestone in our efforts to drive meaningful change in the tobacco industry,” said Michael Zercher, President and Chief Operating Officer of 22nd Century Group.

  • GlobeNewswire

    22nd Century Group Announces Management Changes

    Williamsville, NY, Dec. 13, 2019 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco and hemp/cannabis plant research, announced today changes to the Company’s management. “Over the past few months we have made rapid and significant progress in strengthening 22nd Century Group as we execute against our two growth strategies,” commented James W. Cornell, Director & Chairman of the Board of 22nd Century Group.

  • Benzinga

    22nd Century Enters CBD Space With $24M Investment In Panacea

    Investments are anticipated to total $24 million, in a combination of cash and 22nd Century stock. “Our objective is to build a leading, profitable business in the fast-growing, emerging, legal hemp/cannabis space, and Panacea is a rapidly-growing, vertically-integrated, consumer-facing business with a very strong management team," Cliff Fleet, President and CEO of 22nd Century Group said in a statement.

  • GlobeNewswire

    22nd Century Group Enters CBD Health and Wellness Market with Investment in Panacea Life Sciences, Inc.

    Williamsville, NY, Dec. 03, 2019 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco and hemp/cannabis plant research, announced today the initial closing of an investment in Panacea Life Sciences, Inc. (Panacea), a rapidly-growing, vertically-integrated, consumer-facing company operating exclusively in the legal, hemp-derived, CBD product space. 22nd Century’s investments in Panacea over the next twelve to eighteen months are expected to total $24 million, in a combination of cash and 22nd Century stock in exchange for Panacea-issued debt and preferred equity.

  • Thomson Reuters StreetEvents

    Edited Transcript of XXII earnings conference call or presentation 8-Nov-19 2:00pm GMT

    Q3 2019 22nd Century Group Inc Earnings Call

  • GlobeNewswire

    22nd Century Group Comments on Delay of Reduced Nicotine Rule for Cigarettes

    Williamsville, NY, Nov. 21, 2019 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco and hemp/cannabis research, responded today to the FDA’s recent removal of the Tobacco Product Standard for Nicotine Level of Certain Tobacco Products from the Trump administration’s ‘unified agenda.’  The much anticipated Notice of Proposed Rulemaking (NPRM) for the reduced nicotine product standard, which was expected in October, was listed as being “Withdrawn” as of October 23, 2019, on the White House Office of Information and Regulatory Affairs website. The unified agenda was updated with the new information on Wednesday, November 20, 2019, as part of a semiannual review.

  • GlobeNewswire

    22nd Century Group Announces Webcast to Provide Business Update

    WILLIAMSVILLE, NY -- 22nd Century Group, Inc. (NYSE American:  XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco, and hemp/cannabis plant research, announced today that the Company will provide a business update for investors via an audio-only webcast on Friday, November 8, 2019, at 9:00 AM Eastern time. Cliff Fleet, Chief Executive Officer of 22nd Century Group, together with John Brodfuehrer, Chief Financial Officer, will conduct the webcast. Interested parties are invited to listen to the live event on the 22nd Century website: www.xxiicentury.com/media/2019Q3BusinessUpdate.

  • Does 22nd Century Group (NYSEMKT:XXII) Have A Healthy Balance Sheet?
    Simply Wall St.

    Does 22nd Century Group (NYSEMKT:XXII) Have A Healthy Balance Sheet?

    David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...